IPOs & Funding vs FDA Actions
Side-by-side coverage analysis for IPOs & Funding and FDA Actions.
This comparison applies the same classification pipeline used across every story on this site, which scores each linked entity at a minimum 35 percent relevance threshold before it is surfaced. According to our editorial methodology, reviewed July 2026, this follows multi-source corroboration standards recommended by journalism research bodies such as the Reuters Institute for the Study of Journalism.
IPOs & Funding
Biotech IPOs, venture funding
- Stories
- 7
- Avg Impact
- 5.6/10
- Dominant Tone
- Neutral
- Latest
- Mar 24, 2026
FDA Actions
Approvals, rejections, priority reviews
- Stories
- 73
- Avg Impact
- 6.6/10
- Dominant Tone
- Positive
- Latest
- 2d ago
Recent Headlines
IPOs & Funding
- Sai Parenterals Debuts ₹409-Crore IPO as Pharma Injectables Gain Momentum
- Sunway Healthcare Defies Geopolitical Headwinds in Strong Market Debut
- GSP Crop Science Launches Rs 400 Crore IPO Amid Muted Market Sentiment
- Medtronic’s MiniMed Prices IPO at $20 Per Share, Raising $560 Million
- Medtronic Unit MiniMed Raises $560M in IPO Amid Cautious Market Pricing
- Sunway Healthcare Targets $736M IPO to Fuel Regional Expansion
- Gaudium IVF IPO Enters Final Day with 3x Subscription and Positive GMP
FDA Actions
- 3 in 5 abortions use mifepristone as 5th Circuit weighs limits
- FDA Drug Chief to Oversee 3 Psychedelic Candidates: Psilocybin, MDMA, LSD
- FDA Names 4 Center Directors as Psychedelics Reviews Take Shape
- Mifepristone in 60% of U.S. abortions faces FDA rule fight in 5th Circuit
- Endometriosis tests advance abroad while U.S. lags for 1 in 10 women
- Rasonque Approved: KRAS Inhibitor Doubles Survival to 13.2 Months
- ICP DAS-BMP TPU with 20-40% Barium Sulfate Targets Implantable Devices
- Druckenmiller's Q2 RYTM Bet Targets 2 FDA Nods in Rare Obesity
- Zeon's FDA FSMA + NSF 21 CFR Part 111 cGMP Boost India CDMO Credibility
- Opdivo's 1/12th Dose Shows Efficacy in Indian Study, Sparking FDA Label Debate